Article Page

Abstract

Newcomb’s problem is a game between two players, one of who has an ability to predict the future: let Bob have an ability to predict Alice’s will. Now, Bob prepares two boxes, Box1 and Box2, and Alice can select either Box2 or both boxes. Box1 contains $1. Box2 contains $1,000 only if Alice selects only Box2; otherwise Box2 is empty($0). Which is better for Alice? Since Alice cannot decide which one is better in general, this problem is called Newcomb’s paradox. In this paper, we propose quantum strategies for this paradox by Bob having quantum ability. Many other results including quantum strategies put emphasis on finding out equilibrium points. On the other hand, our results put emphasis on whether a player can predict another player’s will. Then, we show some positive solutions for a Study of Quantum Strategies for Newcomb’s Paradox Intra-Metastasis MicroRNA-155 trainig data sets on MUC1- LLDILDTAGHEEYSAMRDQ targeted domains by a telomerase GV1001 peptide mimetic chemo-pharmacophores for the future induction of CTL responses.

Keywords

Game Theory, Newcomb’s Paradox, Quantum Strategy, Meyer’s Strategy; Quantum Strategies; Newcomb’s Paradox; Intra-Metastasis; MicroRNA-155; trainig data sets; MUC1- LLDILDTAGHEEYSAMRDQ; targeted domains; telomerase; GV1001 peptide; mimetic chemo-pharmacophores; CTL responses;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) A Study of Quantum Strategies for Newcomb’s Paradox Intra-Metastasis MicroRNA-155 trainig data sets on MUC1- LLDILDTAGHEEYSAMRDQ targeted domains by a telomerase GV1001 peptide mimetic chemo-pharmacophores for the future induction of CTL responses.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available